Epilepsy

Mary Anne Meskis; Tracy Dixon-Salazar, PhD; Kelly Knupp, MD; and Joseph E. Sullivan, MD, provide advice for physicians treating patients with Dravet syndrome or LGS.

Kelly Knupp, MD; Mary Anne Meskis; and Tracy Dixon-Salazar, PhD, share education around patient advocacy and support groups as well as other resources for patients with Dravet syndrome or LGS.

Tracy Dixon-Salazar, PhD, leads a discussion on challenges of treating LGS and real-world implications from clinical trial data on newer medications.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 5, 2022.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Alzheimer's Association.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 29, 2022.

Kelly Knupp, MD, provides insight on optimizing treatment for patients with Lennox-Gastaut Syndrome.

Dr Kelly Knupp examines data on fenfluramine and cannabidiol for the management of Lennox-Gastaut Syndrome.

The oral suspension, marked as Ztalmy by developer Marinus, is the first drug approval for cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (also known as CDD), given the greenlight in March. The agent is now available as of July 28, 2022.

Here's some of what is coming soon to NeurologyLive® this week.

The median time to seizure relapse following antiseizure medication discontinuation was 8 months, although 16.7% of the cohort had relapse occur just 1 month after baseline.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Neurology News Network for the week ending July 23, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 22, 2022.

Joseph E. Sullivan, MD, leads a discussion on treatment options for the management of patients with LGS and considers the impact of treatment on quality of life.

Kelly Knupp, MD, shares her perspective of a provider journey of a new patient with LGS and goal setting to manage the disease.

Findings showed between a 2.4- to 5-fold increased risk of autism spectrum disorder and intellectual disability in children with prenatal exposure to valproate, and similar findings for those exposed to topiramate.

Over a year treatment period, patients maintained their subscale scores assessing medication effects, energy and fatigue, and cognition, all of which might be expected to be sensitive to a new treatment.

Previously used to treat conditions such as temporal lobe epilepsy and focal impaired awareness, the FDA approved a new oral suspension of zonisamide, an antiseizure medication on the market for over 2 decades.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 15, 2022.

Tracy Dixon-Salazar, PhD, reflects on her daughter’s journey to diagnosis of Lennox-Gastaut Syndrome and the impact of the disease on caregivers.